Přehled nejdůležitějších metod léčby keratocystického odontogenního tumoru
Autoři:
Azadi Mehdi 1; Bashar Saeed 2; Hajiani Narges 1; Amiri Hooman 1; Azadi Sepehr 3; Ansari Zahra 4
Působiště autorů:
Resident of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tehran University of Medical sciences, Tehran, Iran
1; Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Golestan University of Medical Sciences, Gorgan, Iran
2; Dentistry Student, Faculty of Dentistry, Zanjan University of Medical Sciences, Zanjan, Iran
3; Doctor of Dental Surgery (DDS), DMD, Tehran, Iran
4
Vyšlo v časopise:
Klin Onkol 2022; 35(1): 10-19
Kategorie:
Přehledy
doi:
https://doi.org/10.48095/ccko202210
Souhrn
Východiska: Keratocystický odontogenní tumor (keratocystic odontogenic tumor – KCOT) je rekurentní benigní tumor tvaru keratinizovaného epitelu. Způsob léčby je stále předmětem diskusí. Cílem všech léčebných metod je eradikace cysty a omezení rekurence a pooperačních komplikací. Tento přehledový článek byl vytvořen s cílem zhodnotit závěry studií zaměřených na diagnostiku, léčbu a rekurenci KCOT. Metody: Informace byly shromažďovány po zadání slov management, léčba, farmakologie, operace a keratocystický odontogenní tumor do mezinárodních databází Web of Science, PubMed a Scopus. Sledování dat probíhalo v období let 2010–2020. Výsledky: Mezi techniky používané při léčbě patří dekomprese, marsupializace, enukleace s následnou operací čelistní dutiny ze zevního přístupu dle Caldwell-Luca nebo bez ní a resekce. Ze 40 studií byla rekurence pozorována v 13 studiích a u různých léčebných metod se pohybovala v rozmezí 0–48 %. Závěr: V důsledku vysoké rekurence onemocnění se po léčbě doporučuje dlouhodobé sledování. Rozhodnutí o způsobu léčby by mělo zohledňovat věk pacienta, velikost nádoru a místo výskytu, aby se co nejvíce snížila ekonomická a psychická zátěž tímto onemocněním.
Klíčová slova:
léčba – operace – farmakologie – management – keratocystický odontogenní tumor
Zdroje
1. Philipsen HP. Keratocystic odontogenic tumour. In: Barnes L, Eveson J, Reichart P et al (eds). Pathology and genetics of head and neck tumours, WHO classification of tumours. Lyon: IARC Press 2005: 306–307.
2. Chemli H, Dhouib M, Karray F et al. Risk factors for recurrence of maxillary odontogenic keratocysts. Rev Stomatol Chir Maxillofac 2010; 111 (4): 189–192. doi: 10.1016/j.stomax.2009.07.011.
3. Neville BW, Damm DD, Allen CM et al. Color atlas of oral and maxillofacial diseases. Elsevier Health Sciences 2018.
4. Mendes RA, Carvalho JFC, van der Waal I. Characterization and management of the keratocystic odontogenic tumor in relation to its histopathological and biological features. Oral Oncol 2010; 46 (4): 219–225. doi: 10.1016/j.oraloncology.2010.01.012.
5. Suemitsu M. A pathomorphological study of fractal analysis in parenchymal-stromal border on keratocystic odontogenic tumor – with special reference to proliferative activity and vascular distribution. Int J Oral Med Sci 2012; 10 (4): 372–383. doi: 10.5466/ijoms.10.372.
6. Okamoto E, Kikuchi K, Miyazaki Y et al. Significance of podoplanin expression in keratocystic odontogenic tumor. J Oral Pathol Med 2010; 39 (1): 110–114. doi: 10.1111/j.1600-0714.2009.00851.x.
7. Buckley PC, Seldin EB, Dodson TB et al. Multilocularity as a radiographic marker of the keratocystic odontogenic tumor. J Oral Maxillofac Surg 2012; 70 (2): 320–324. doi: 10.1016/j.joms.2011.03.012.
8. Neville B, Damm DD, Allen C. Oral and maxillofacial pathology. Philadelphia 2002.
9. Kaneda T, Minami M, Kurabayashi T. Benign odontogenic tumors of the mandible and maxilla. Neuroimaging Clin N Am 2003; 13 (3): 495–507. doi: 10.1016/s1052-5149 (03) 00032-7.
10. Kakarantza-Angelopoulou E, Nicolatou O. Odontogenic keratocysts: clinicopathologic study of 87 cases. J Oral Maxillofac Surg 1990; 48 (6): 593–599. doi: 10.1016/s0278-2391 (10) 80472-0.
11. Brannon RB. The odontogenic keratocyst: a clinicopathologic study of 312 cases. Part II. Histologic features. Oral Surg Oral Med Oral Pathol 1977; 43 (2): 233–255. doi: 10.1016/0030-4220 (77) 90161-x.
12. Kolokythas A, Fernandes RP, Pazoki A et al. Odontogenic keratocyst: to decompress or not to decompress? A comparative study of decompression and enucleation versus resection/peripheral ostectomy. J Oral Maxillofac Surg 2007; 65 (4): 640–644. doi: 10.1016/j.joms.2006.06.284.
13. Tolstunov L, Treasure T. Surgical treatment algorithm for odontogenic keratocyst: combined treatment of odontogenic keratocyst and mandibular defect with marsupialization, enucleation, iliac crest bone graft, and dental implants. J Oral Maxillofac Surg 2008; 66 (5): 1025–1036. doi: 10.1016/j.joms.2007.08.014.
14. Pogrel MA. Treatment of keratocysts: the case for decompression and marsupialization. J Oral Maxillofac Surg 2005; 63 (11): 1667–1673. doi: 10.1016/j.joms.2005.08.008.
15. Stoor P, Apajalahti S, Kontio R. Regeneration of cystic bone cavities and bone defects with bioactive glass S53P4 in the upper and lower jaws. J Craniofac Surg 2017; 28 (5): 1197–1205. doi: 10.1097/SCS.0000000000003 649.
16. Al-Moraissi EA, Pogrel MA, Ellis E 3rd. Enucleation with or without adjuvant therapy versus marsupialization with or without secondary enucleation in the treatment of keratocystic odontogenic tumors: a systematic review and meta-analysis. J Craniomaxillofac Surg 2016; 44 (9): 1395–1403. doi: 10.1016/j.jcms.2016.05.020.
17. Pogrel MA. Decompression and marsupialization as definitive treatment for keratocysts – a partial retraction. J Oral Maxillofac Surg 2007; 65 (2): 362–363. doi: 10.1016/j.joms.2006.09.032.
18. Wushou A, Zhao YJ, Shao ZM. Marsupialization is the optimal treatment approach for keratocystic odontogenic tumour. J Craniomaxillofac Surg 2014; 42 (7): 1540–1544. doi: 10.1016/j.jcms.2014.04.027.
19. Pogrel MA. Treatment of keratocysts: the case for decompression and marsupialization. J Oral Maxillofac Surg 2005; 63 (11): 1667–1673. doi: 10.1016/j.joms.2005.08.008.
20. de Castro MS, Caixeta CA, de Carli ML et al. Conservative surgical treatments for nonsyndromic odontogenic keratocysts: a systematic review and meta-analysis. Clin Oral Investig 2018; 22 (5): 2089–2101. doi: 10.1007/s00784-017-2315-8.
21. Maurette PE, Jorge J, de Moraes M. Conservative treatment protocol of odontogenic keratocyst: a preliminary study. J Oral Maxillofac Surg 2006; 64 (3): 379–383. doi: 10.1016/j.joms.2005.11.007.
22. Tabrizi R, Hosseini Kordkheili MR, Jafarian M et al. Decompression or marsupialization; which conservative treatment is associated with low recurrence rate in keratocystic odontogenic tumors? A systematic review. J Dent (Shiraz) 2019; 20 (3): 145–151. doi: 10.30476/DENTJODS.2019.44899.
23. Jensen J, Sindet-Pedersen S, Simonsen EK. A comparative study of treatment of keratocysts by enucleation or enucleation combined with cryotherapy. A preliminary report. J Craniomaxillofac Surg 1988; 16 (8): 362–365. doi: 10.1016/s1010-5182 (88) 80080-5.
24. Leung YY, Lau SL, Tsoi KY et al. Results of the treatment of keratocystic odontogenic tumours using enucleation and treatment of the residual bony defect with Carnoy‘s solution. Int J Oral Maxillofac Surg 2016; 45 (9): 1154–1158. doi: 10.1016/j.ijom.2016.02.002.
25. Cutler EC, Zollinger R. The use of sclerosing solutions in the treatment of cysts and fistulae. Am J Surg 1933; 19 (3): 411–418. doi: 10.1016/S0002-9610 (33) 90796-5.
26. Morgan TA, Burton CC, Qian F. A retrospective review of treatment of the odontogenic keratocyst. J Oral Maxillofac Surg 2005; 63 (5): 635–639. doi: 10.1016/j.joms.2004.07.026.
27. Voorsmit RA, Stoelinga PJ, van Haelst UJ. The management of keratocysts. J Maxillofac Surg 1981; 9 (4): 228–236. doi: 10.1016/s0301-0503 (81) 80049-5.
28. Madhulaxmi M, Wahab PU. Carnoy‘s solution as a surgical medicament in the treatment of keratocystic odontogenic tumour. Int J Pharm Bio Sci 2014; 5 (1): B492–B495.
29. Júnior OR, Borba AM, Alves CAF et al. Carnoy’s solution over the inferior alveolar nerve as a complementary treatment for keratocystic odontogenic tumors. Rev Clin Pesq Odontol 2007; 3 (3): 199–202.
30. Al-Moraissi EA, Dahan AA, Alwadeai MS et al. What surgical treatment has the lowest recurrence rate following the management of keratocystic odontogenic tumor?: A large systematic review and meta-analysis. J Craniomaxillofac Surg 2017; 45 (1): 131–144. doi: 10.1016/j.jcms.2016.10.013.
31. Chrcanovic BR, Gomez RS. Recurrence probability for keratocystic odontogenic tumors: an analysis of 6427 cases. J Craniomaxillofac Surg 2017; 45 (2): 244–251. doi: 10.1016/j.jcms.2016.11.010.
32. Lebedev VV, Butsan SB. The use of Carnoy’s solution and its modifications for reducing the number of recurrences after surgical removal of keratocystic odontogenic tumors and ameloblastomas: a systematic review. Moscow Uni Biol Sci Bull 2019; 74 (2): 108–116. doi: 10.3103/S0096392519020068.
33. Alchalabi NJ, Merza AM, Issa SA. Using Carnoy‘s solution in treatment of keratocystic odontogenic tumor. Ann Maxillofac Surg 2017; 7 (1): 51–56. doi: 10.4103/ams.ams_127_16.
34. Blanas N, Freund B, Schwartz M et al. Systematic review of the treatment and prognosis of the odontogenic keratocyst. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90 (5): 553–558. doi: 10.1067/moe. 2000.110814.
35. Warburton G, Shihabi A, Ord RA. Keratocystic odontogenic tumor (KCOT/OKC) – clinical guidelines for resection. J Maxillofac Oral Surg 2015; 14 (3): 558–564. doi: 10.1007/s12663-014-0732-7.
36. Titinchi F, Nortje CJ. Keratocystic odontogenic tumor: a recurrence analysis of clinical and radiographic parameters. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114 (1): 136–142. doi: 10.1016/j.oooo.2012.01.032.
37. Agrawal R, Sangle A, Vyawahare A. Bismuth iodoform and paraffin paste: a boon in treatment of keratocystic odontogenic tumor: a case report. Int J Dent Med Res 2014; 1 (2): 32–35.
38. Borgonovo AE, Di Lascia S, Grossi G et al. Two-stage treatment protocol of keratocystic odontogenic tumour in young patients with Gorlin-Goltz syndrome: marsupialization and later enucleation with peripheral ostectomy. A 5-year-follow-up experience. Int J Pediatr Otorhinolaryngol 2011; 75 (12): 1565–1571. doi: 10.1016/j.ijporl.2011.09.009.
39. Cassoni A, Valentini V, Della Monaca M et al. Keratocystic odontogenic tumor surgical management: retrospective analysis on 77 patients. Eur J Inflamm 2014; 12 (1): 209–215. doi: 10.1177/1721727X1401200123.
40. Davoodi P, Soufi L, Rezaei-soufi L et al. Submandibular abscess due to an infected keratocystic odontogenic tumor associated with simultaneous occurrence of a traumatic bone cyst: a rare case report. J Contemp Dent Pract 2013; 14 (1): 133–136. doi: 10.5005/jp-journals-10024-1286.
41. Deboni MCZ, Brozoski MA, Traina AA et al. Surgical management of dentigerous cyst and keratocystic odontogenic tumor in children: a conservative approach and 7-year follow-up. J App Oral Sci 2012; 20 (2): 282–285. doi: 10.1590/s1678-77572012000200025.
42. de Molon RS, Verzola MH, Pires LC et al. Five years follow-up of a keratocyst odontogenic tumor treated by marsupialization and enucleation: a case report and literature review. Contemp Clin Dent 2015; 6 (Suppl 1): S106–S110. doi: 10.4103/0976-237X.152963.
43. Ebenezer V, Ramalingam B. Importance of different modalities of treatment for the management of keratocystic odontogenic tumour with five year follow-up. J Clin Diagn Res 2014; 8 (3): 225–228. doi: 10.7860/JCDR/2014/7486.4168.
44. Güler N, Şençift K, Demirkol Ö. Conservative management of keratocystic odontogenic tumors of jaws. ScientificWorldJournal 2012; 2012: 680397. doi: 10.1100/2012/680397.
45. Gao L, Wang XL, Li SM et al. Decompression as a treatment for odontogenic cystic lesions of the jaw. J Oral Maxillofac Surg 2014; 72 (2): 327–333. doi: 10.1016/j.joms.2013.07.035.
46. Caixeta Guimarães A, Dutra de Cassia Ferreira Santos M, Machado de Carvalho G et al. Giant keratocystic odontogenic tumor: three cases and literature review. Iran J Otorhinolaryngol 2013; 25 (73): 245–252.
47. Hasheminia D, Naemi V, Naghdi N. Conservative treatment protocol of keratocystic odontogenic tumor: report of a case with nevoid Basal cell carcinoma syndrome and literature review. J Maxillofac Oral Surg 2015; 14 (Suppl 1): 475–481. doi: 10.1007/s12663-014-0689-6.
48. Kebede B, Dejene D, Teka A et al. Big keratocytic odontogenic tumor of the mandible: a case report. Ethiop J Health Sci 2016; 26 (5): 491–496. doi: 10.4314/ejhs.v26i5.12.
49. Kim SH, Oh MS, Seo YS et al. Conservative treatment of multiple keratocystic odontogenic tumors in a young patient with nevoid Basal cell carcinoma syndrome by decompression: a 7-year follow-up study. J Clin Pediatr Dent 2017; 41 (4): 300–304. doi: 10.17796/1053-4628-41.4.300.
50. Koçak-Berberoğlu H, Çakarer S, Brkić A et al. Three-dimensional cone-beam computed tomography for diagnosis of keratocystic odontogenic tumours; evaluation of four cases. Med ral Patol Oral Cir Bucal 2012; 17 (6): e1000–e1005. doi: 10.4317/medoral.17629.
51. Kunihiro T, Kawana H, Kodaka R et al. Keratocystic odontogenic tumor invading the maxillary sinus: a case report of collaborative surgery between an oral surgeon and an otorhinolaryngologist. J UOEH 2014; 36 (4): 251–256. doi: 10.7888/juoeh.36.251.
52. Lacarbonara M, Marzo G, Lacarbonara V et al. Presentation of a keratocystic odontogenic tumor with agenesis: a case report. J Med Case Rep 2014; 8: 126. doi: 10.1186/1752-1947-8-126.
53. Ledderhof NJ, Caminiti MF, Bradley G et al. Topical 5-fluorouracil is a novel targeted therapy for the keratocystic odontogenic tumor. J Oral Maxillofac Surg 2017; 75 (3): 514–524. doi: 10.1016/j.joms.2016.09.039.
54. Liu B, Cai Y, Wang SP et al. Recurrent keratocystic odontogenic tumor in the masseter muscle overlying the boney perforations: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 113 (4): e1–5. doi: 10.1016/j.tripleo.2011.07.005.
55. Zhao Y, Liu B, Cheng G et al. Recurrent keratocystic odontogenic tumours: report of 19 cases. Dentomaxillofac Radiol 2012; 41 (2): 96–102. doi: 10.1259/dmfr/22891 281.
56. Morais de Melo W, Pereira-Santos D, Sonoda CK et al. Decompression for management of keratocystic odontogenic tumor in the mandible. J Craniofac Surg 2012; 23 (6): e639–e640. doi: 10.1097/SCS.0b013e31827101e9.
57. Motwani MB, Mishra SS, Anand RM et al. Keratocystic odontogenic tumor: case reports and review of literature. J Indian Academy Oral Med Radiol 2011; 23 (2): 150–154. doi: 10.5005/jp-journals-10011-1117.
58. Naruse T, Yamashita K, Yanamoto S et al. Histopathological and immunohistochemical study in keratocystic odontogenic tumors: predictive factors of recurrence. Oncol Lett 2017; 13 (5): 3487–3493. doi: 10.3892/ol.2017. 5905.
59. Nomura K, Arakawa K, Fujishima F et al. Minimally invasive treatment for hard palate-invading maxillary keratocystic odontogenic tumor. Tohoku J Exp Med 2015; 237 (4): 267–272. doi: 10.1620/tjem.237.267.
60. Ohki M. Transnasal marsupialization using endoscopic sinus surgery for treatment of keratocystic odontogenic tumor in maxillary sinus. Case Rep Otolaryngol 2012; 2012: 281402. doi: 10.1155/2012/281402.
61. Ribeiro Junior O, Borba AM, Alves CA et al. Keratocystic odontogenic tumors and Carnoy‘s solution: results and complications assessment. Oral Dis 2012; 18 (6): 548–557. doi: 10.1111/j.1601-0825.2012.01907.x.
62. Roopak B, Singh M, Shah A et al. Keratocystic odontogenic tumor: treatment modalities: study of 3 cases. Niger J Clin Pract 2014; 17 (3): 378–383. doi: 10.4103/1119-3077.130251.
63. Scartezini GR, Oliveira GC, Guedes OA et al. Diagnostic and treatment features of keratocystic odontogenic tumors. Stomatos 2012; 18 (35): 9–15.
64. Schussel JL, Stramandinoli RT, Dissenha JL et al. Retrospective study of 25 cases of keratocystic odontogenic tumor: epidemiology and treatment. J Contemp Dent Pract 2011; 12 (2): 100–103. doi: 10.5005/jp-journals-10024-1016.
65. Bharani KS, Lakshmi SS, Kamath AR et al. Keratocystic odontogenic tumor: case report, treatment review and future diagnostic trends. J Oral Maxillofacial Surg Med Pathol 2013; 25 (1): 85–92.
66. Srivatsan K, Kumar V, Mahendra A et al. Bilateral keratocystic odontogenic tumor: a report of two cases. Natl J Maxillofac Surg 2014; 5 (1): 86–89. doi: 10.4103/0975-5950.140186.
67. Sivanmalai S, Kandhasamy K, Prabu N et al. Carnoy‘s solution in the mangement of odontogenic keratocyst. J Pharm Bioallied Sci 2012; 4 (Suppl 2): S183–S185. doi: 10.4103/0975-7406.100266.
68. Vázquez-Romero MD, Serrera-Figallo ML, Alberdi-Navarro J et al. Maxillary peripheral keratocystic odontogenic tumor. A clinical case report. J Clin Exp Dent 2017; 9 (1): e167–e171. doi: 10.4317/jced.53438.
69. Warburton G, Shihabi A, Ord RA. Keratocystic odontogenic tumor (KCOT/OKC) –clinical guidelines for resection. J Maxillofac Oral Surg 2015; 14 (3): 558–564. doi: 10.1007/s12663-014-0732-7.
70. Zhou J, Wang L, Chen Z et al. Giant keratocystic odontogenic tumor of the maxillary sinus and zygoma: a case report. Oncol Lett 2014; 8 (6): 2675–2677. doi: 10.3892/ol.2014.2576.
71. Yang S-I, Park Y-I, Choi S-Y et al. A retrospective study of 220 cases of keratocystic odontogenic tumor (KCOT) in 181 patients. Asian J Oral Maxillofac Surg 2011; 23 (3): 117–121. doi: 10.1016/j.ajoms.2011.03.002.
72. Yildirim G, Ataoglu H, Kalayci A et al. Conservative treatment protocol for keratocystic odontogenic tumour: a follow-up study of 3 cases. J Oral Maxillofac Res 2010; 1 (3): e7. doi: 10.5037/jomr.2010.1307.
73. Jafaripozve N, Jafaripozve S, Khorasgani MA. Kerathocyst odontogenic tumor: importance of selection the best treatment modality and a periodical follow-up to prevent from recurrence: a case report and literature review. Int J Prev Med 2013; 4 (8): 967–970.
74. Ribeiro-Júnior O, Borba AM, Alves CAF et al. Reclassification and treatment of odontogenic keratocysts: a cohort study. Braz Oral Res 2017; 31: e98. doi: 10.1590/1807-3107bor-2017.vol31.0098.
75. Oliveira A, Ferrisse T, Pereira-Filho V et al. Treatment of a large keratocystic odontogenic tumor in a mandible using decompression technique followed by enucleation. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 2017; 124 (2): e96. doi: 10.1016/j.oooo.2017.05.187.
Štítky
Dětská onkologie Chirurgie všeobecná OnkologieČlánek vyšel v časopise
Klinická onkologie
2022 Číslo 1
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Prof. Petra Tesařová: Pacientky s metastatickým karcinomem nemají čas čekat na výsledky zdlouhavých byrokratických procedur
- Cinitaprid – nové bezpečné prokinetikum s odlišným mechanismem účinku
- Cinitaprid v léčbě funkční dyspepsie – přehled a metaanalýza aktuálních dat
Nejčtenější v tomto čísle
- Praktické aspekty terapie CAR-T lymfocyty
- Rehabilitácia a pohybová aktivita u pacientov s rakovinou pľúc
- Přehled nejdůležitějších metod léčby keratocystického odontogenního tumoru
- Podtřída imunoglobulinů IgG4 a s ní související patologické stavy aneb jak účinně imitovat nádorové onemocnění